Clinical Read2026-06-14

Olverembatinib (HQP1351) and Lisaftoclax (APG-2575)

Ascentage Pharma Group InternationalAAPG
Indication
Relapsed/refractory Ph+ ALL
Stage
phase1
Event
Phase 1b